Home » Newsletters » BioWorld Science

BioWorld Science

April 3, 2006

View Archived Issues

Malaria vaccines safe in early investigations

Galantamine and smoking cessation / News in Context

Cyclacel completes Xcyte transactions

University of Washington to study effects of TH-9507 on cognitive function

Provigil granted six months of pediatric exclusivity

Launch activities continue for Yaz

TNFerade begins new phase II study in metastatic melanoma

First clinical trials demonstrate transdermal delivery of hPTH (1-34)

Reinitiation of Tysabri clinical trial dosing in multiple sclerosis

Relenza approved for prophylactic use, GSK advances pandemic flu vaccines

Eisai and DNAVEC collaborate on Alzheimer's disease vaccine

sBLA submission for first-line use of Rituxan in NHL

New phase II trial investigates erdosteine for COPD-associated chronic bronchitis

Fast track designation for PTC-124 in Duchenne muscular dystrophy

IND cleared for clinical studies of NIC5-15 for Alzheimer's disease

First clinical trial of gene therapy for muscular dystrophy now under way

Results of phase II study of surfactant lavage for ARDS

Lacosamide has clinically relevant effect in neuropathic pain

Maribavir significantly reduces CMV reactivation

New therapeutics for cancer covered in recent patent literature

Recent patents report new treatments for depression, anxiety, sleep disorders, etc.

Recent Array BioPharma patent discloses novel agents for immunoregulatory disorders

Prograf approved for use in heart transplant patients

NDA submitted for intravenous RSD-1235

Takeda submits NDA for ACTOplus met XR

In vivo antitumor efficacy of TL-310 reported, compound advanced into clinic

TPI-287 demonstrates good oral activity and greater potency than paclitaxel in preclinical studies

Novel series of VLA-1 integrin inhibitors developed by Icos

Spotlight on liver X receptor agonists as potential antiatherosclerotic drugs

Approvable letter for Xenazine in Huntington's disease-associated chorea